Efficacy and Safety of the CG-100 Intraluminal Bypass Device
Recruiting
N/A
Interventional Study
Rectal Cancer
Rectal Tumor
Rectal/Anal
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 22 – 70
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 250 (estimated)
- Sponsor
- Colospan Ltd. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
A randomized trial to assess the safety and efficacy of CG-100 for reducing stoma creation rate in subjects undergoing mesorectal excision.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. The patient is willing to comply with protocol-specified follow-up evaluations
2. Patient 22-65 years of age at screening, or patient 66-70 years of age at screening with up to one cardiovascular, metabolic or pulmonary comorbidity for which medication is prescribed.
3. Patie…
Contacts